ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has completed the sale of its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V., to AVS Bio for a total enterprise value of $12 million USD. The transaction, which generated $11.7 million USD in net proceeds on a cash-free, debt-free basis, represents a strategic pivot toward the company's AI-driven drug discovery capabilities.
AVS Bio, a portfolio company of Arlington Capital Partners, is a leading global provider of critical inputs and services for the bioprocessing and biologics industries. The acquisition adds to AVS Bio's network of more than 20 facilities across North America and Europe, where the company supplies specific pathogen-free (SPF) laboratory products including SPF eggs, antigens, and antibodies to support vaccine and therapeutic development.
Strategic Focus on AI-Powered Biologics Discovery
The divestiture marks a significant step in IPA's strategic refinement, allowing the company to streamline its operational footprint and concentrate resources on its most impactful growth areas. The proceeds will support investment in scientific platforms, data-driven discovery technologies, and expansion of key strategic programs.
"This transaction delivers strong value to IPA and our investors," said Dr. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies Ltd. "It reflects our disciplined strategy to focus resources on our AI-based Software as a Service (SaaS) platform—where we're combining scientific expertise with advanced technologies to accelerate modern biologics discovery."
LENSai™ Platform Technology
IPA's global operations now center around biologics discovery, engineering, and characterization, supported by LENSai™, the company's proprietary platform powered by HYFT® multi-omics technology. The platform helps unify and interpret complex biological data, enabling more integrated insights and smarter decisions across the discovery and development process.
By harmonizing data across modalities, LENSai™ supports faster identification of opportunities and reduces inefficiencies that typically slow biologics innovation. This technology represents IPA's core competitive advantage as the company transitions toward AI-native drug discovery solutions.
Transaction Details and Future Operations
The sale was conducted through a competitive, arm's-length process with Edgemont Partners serving as exclusive financial advisor to IPA. A 12-month Transition Services Agreement (TSA) will provide continuity across key functions during the transition period, ensuring minimal disruption to ongoing operations.
IPA holds no material ongoing relationship with AVS Bio or its affiliates beyond the scope of this transaction. The company continues to support global partners in advancing novel therapeutics, diagnostics, and translational research through its remaining operations and technology platforms.
Arlington Capital Partners, the private investment firm behind AVS Bio, specializes in government-regulated industries and has invested in over 175 companies since its inception in 1999. The firm is currently investing out of its $3.8 billion Fund VI, focusing on strategically important businesses in healthcare, government services, technology, aerospace, and defense sectors.
